Clinical Trials Logo

Clinical Trial Summary

This is a single-center, single-arm, dose escalation study, to explore the safety, tolerability and efficacy of human amniotic epithelial stem cells (hAESCs) for idiopathic Parkinson's disease (PD).


Clinical Trial Description

hAESCs will be administration through the Ommaya reservoir implanted into the lateral ventricle of subjects with idiopathic PD. This dose escalation will be followed by an exploratory expansion phase in 3 cohorts. - Dose A (5×10^7 cells/dose) - Dose B (1.0×10^8 cells/dose) - Dose C (1.5×10^8 cells/dose). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05691114
Study type Interventional
Source Shanghai East Hospital
Contact Jingwen Wu, M.D.
Phone 021-38804518
Email wujingwendongfang@163.com
Status Recruiting
Phase Phase 1
Start date February 2023
Completion date February 2026

See also
  Status Clinical Trial Phase
Completed NCT03665493 - Dopamine Effect on Inhibitory Control N/A
Completed NCT02227355 - Evaluating the Effectiveness of Neupro® (Rotigotine) and L-dopa Combination Therapy in Patients With Parkinson's Disease N/A
Completed NCT01026428 - A Study to Assess the Effect of Safinamide on Levodopa Pharmacokinetics Phase 1/Phase 2
Completed NCT00664157 - Facial Expression Recognition of Emotion and Categorization of Emotional Words in Parkinson's Disease. Impact of L-Dopa and Deep Brain Stimulation of Subthalamic Nucleus N/A
Completed NCT04524143 - The Acute Effect of Cervical Mobilization in Parkinson's Disease N/A
Completed NCT05107531 - Investigation of Gait, Foot Pressure Distribution and Balance in Parkinson's Patients With Motor Freezing
Completed NCT04524182 - The Acute Effect of Lumbosacral Mobilization in Parkinson's Disease N/A
Completed NCT00985517 - Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease Phase 1/Phase 2
Completed NCT01968031 - A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease Phase 3
Completed NCT01970813 - Efficacy of Acupuncture and Bee Venom Acupuncture on Patients With Idiopathic Parkinson's Disease N/A
Completed NCT01221948 - Vercise Implantable Stimulator for Treating Parkinson's Disease Phase 2
Terminated NCT01028586 - MOTION, Safinamide in Early Idiopathic Parkinson's Disease (IPD), as add-on to Dopamine Agonist (Extension of Trial 27918) Phase 3
Completed NCT00239564 - Pharmacokinetics and Pharmacodynamics of IPX054 in Subjects With Parkinson's Disease Phase 1/Phase 2
Completed NCT02240030 - Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes Phase 3
Completed NCT00605683 - MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist Phase 3
Completed NCT00400634 - Double-Blind, Multicenter, Sham Surgery Controlled Study of CERE-120 in Subjects With Idiopathic Parkinson's Disease Phase 2
Completed NCT01227265 - Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037) Phase 3
Completed NCT02565628 - PF-06669571 In Subjects With Idiopathic Parkinson's Disease Phase 1
Completed NCT01606670 - Observational Study With Neupro® to Evaluate the Patient´s Perception of Pain Associated With Parkinson´s Disease
Completed NCT01617135 - Safety, Pharmacokinetics and Efficacy Study of CVT-301 Inpatients With Parkinson's Disease and "Off" Episodes Phase 2